Scientific Poster Session II - Original Research

Abstract

Research Question or Hypothesis: The purpose of this study was to describe the use of TXA for treatment of ACEi-AE in the ED.

Study Design: This was an institutional review board-approved, single-center, retrospective evaluation of patients aged 18 years or older who presented with ACEi-AE.

Methods: Patients who were admitted and discharged between April 1, 2021 and November 30, 2023 were screened and included if they had a recent history of ACE inhibitor use and were treated with TXA in the ED. Patients were excluded if they had a family history of hereditary or acquired angioedema; received icatibant, ecallantide, or complement-1 esterase inhibitors prior to TXA administration; or were admitted to Trauma services. Descriptive statistics are used to report all outcomes.

Results: A total of 56 patients were included in this study. Over 90% of patients experienced partial or complete resolution of symptoms following TXA administration. Three patients required intubation. Forty-eight percent of patients were transferred to the floor while 34% were discharged home from the ED. All patients survived to hospital discharge. Five patients returned to the ED within 90 days for a recurrent angioedema episode.

Conclusion: Administration of TXA to patients presenting to the ED with ACEi-AE was associated with partial or complete resolution of symptoms. These findings may support incorporation of TXA into standard of care for ACEi-AE in the ED.

Presenting Author

Authors